© EQS Newswire
22.07.2025
SRT3
LISTED
XETR
Sartorius continues growth course; earnings rise at a significantly overproportionate rate
News Preview
Göttingen, Germany | July 22, 2025
Sartorius continues growth course; earnings rise at a significantly overproportionate rate
Group sales revenue up 6.1 percent in the first six months
As expected, continued positive trend in recurring business with consumables
Bioprocess Solutions Division grows by almost 9 percent, lab division still muted as ......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.07.2025
SRT3
LISTED
XETR
Sartorius weiter auf Wachstumskurs, Ertrag steigt deutlich überproportional
News Preview
Göttingen, 22. Juli 2025
Sartorius weiter auf Wachstumskurs, Ertrag steigt deutlich überproportional
Konzernumsatz legt in den ersten sechs Monaten um 6,1 Prozent zu
Wie erwartet anhaltend positiver Trend im Wiederholgeschäft mit Verbrauchsmaterialien
Sparte Bioprocess Solutions wächst um fast 9 Prozent, Laborsparte erwartungsgemäß mit noch ......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.07.2025
DIM
LISTED
EURONEXT
Half-year results 2025 of Sartorius Stedim Biotech
News Preview
Sartorius Stedim Biotech SA
/ Key word(s): Half Year Results
Half-year results 2025 of Sartorius Stedim Biotech 22-Jul-2025 / 07:00 CET/CEST
Aubagne, France | July 22, 2025Half-year results 2025 of Sartorius Stedim Biotech
Sales revenue at 1,490 million euros, up 9.4 percent in constant currencies1 (reported: 8.5 percent)
A......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
22.07.2025
BAVA
LISTED
CPH
Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine
News Preview
COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 ye...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
21.07.2025
EVT
LISTED
XETR
Evotec passt Umsatzprognose an und bestätigt Gewinnprognose; profitablerer Umsatzmix erwartet
News Preview
Erfolgreiche Umsetzung der neuen Strategie für nachhaltiges und profitables Wachstum führt zu einem veränderten Umsatzmix, getrieben durch die starke Nachfrage nach Evotecs differenzierten Plattformen
Margenstarke Technologie-Lizenzeinnahmen werden sich voraussichtlich stärker als erwartet auswirken
Deutliche Kostenoptimierung übert......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.07.2025
EVT
LISTED
XETR
Evotec adjusts revenue guidance and confirms profit guidance anticipating a more profitable revenue mix
News Preview
Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec’s differentiated platforms
High-margin technology license revenues expected to have a stronger impact than anticipated
Significant cost optimization in excess of initial targets from Priority Reset......
Themefolio
Profiler
Peergroup
© Globe Newswire
21.07.2025
AMRX
LISTED
NASDAQ
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
News Preview
– Results Reflect Continued Financial Strength and Deleveraging –...
Themefolio
Profiler
Peergroup
© EQS Newswire
21.07.2025
EVT
LISTED
XETR
Evotec SE passt Umsatzprognose an und bestätigt Gewinnprognose
News Preview
Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014
Ad hoc: Evotec SE passt Umsatzprognose an und bestätigt Gewinnprognose
Hamburg – Die Evotec SE (Frankfurter Wertpapierbörse: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) gibt bekannt, dass sie ihre Umsatzprognose für d......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.07.2025
EVT
LISTED
XETR
Evotec SE adjusts revenue guidance while confirming profit guidance
News Preview
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
Ad hoc: Evotec SE adjusts revenue guidance while confirming profit guidance
Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has updated its reve......
Themefolio
Profiler
Peergroup
© Globe Newswire
21.07.2025
AUTL
LISTED
NASDAQ
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
News Preview
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.07.2025
NSIS B
LISTED
CPH
Major shareholder announcement
News Preview
Please read the full announcement in PDF....
Themefolio
Profiler
Peergroup
© PR Newswire
21.07.2025
RAY B
LISTED
STO
AKSM/Oncology selects RayCare and RayStation for a new cancer center
News Preview
STOCKHOLM, July 21, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that AKSM/Oncology has selected RayCare®* oncology information system and RayStation®* treatment planning system for Advanced Radiation Therapeutics (ART), a new partnership with Urology Associates of The Central Coast in San Luis Obispo in California...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
21.07.2025
ORNBV
LISTED
HEL
Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
News Preview
ORION CORPORATION PRESS RELEASE 21 JULY 2025 at 10:30 EEST ...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
21.07.2025
EVT
LISTED
XETR
Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix
News Preview
Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platformsHigh-margin technology license revenues expected to have a stronger impactthan anticipatedSignificant cost optimization in excess of initial targets from Priority ResetShared R&D base...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
21.07.2025
EVT
LISTED
XETR
Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance
News Preview
HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Guidance on R&D expenses and adjusted EBITDA remains unchanged.For the current fiscal year, the Company...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.07.2025
ZEAL
LISTED
CPH
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
News Preview
Company announcement – No. 17 / 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
18.07.2025
RAY B
LISTED
STO
RaySearch and Radiology Oncology Systems in strategic partnership to expand access to cancer care
News Preview
STOCKHOLM, July 18, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) and Radiology Oncology Systems, Inc. (ROS) are pleased to announce a strategic partnership, aiming at identifying and pursuing opportunities involving both emerging and existing technologies, with focus on the integration of refurbished linear accelerators with advanced sof...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.07.2025
FAGR
LISTED
EURONEXT
Disclosure of notification received from Alychlo
News Preview
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 18 July 2025 – 6 PM CET...
Themefolio
Profiler
Peergroup
© BusinessWire
18.07.2025
ERF
LISTED
EURONEXT
Eurofins Scientific: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF T...
Themefolio
Profiler
Peergroup
© PR Newswire
18.07.2025
RAY B
LISTED
STO
Invitation to presentation of RaySearch's interim report for the second quarter of 2025
News Preview
STOCKHOLM, July 18, 2025 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the second quarter of 2025, on August 8, 2025, at 10.00 am CEST. The report will be published on August 8, 2025, at 07.45 am and will be available together with presentation slides on raysearchlabs.com. Johan...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.07.2025
ORNBV
LISTED
HEL
Orion Group Half-Year Financial Report January–June 2025
News Preview
ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2025 18 JULY 2025 at 12:00 EEST...
Themefolio
Profiler
Peergroup
© PR Newswire
18.07.2025
GETI B
LISTED
STO
Getinge Interim Report April-June 2025: Continuing positive trend with stable organic sales growth in all business areas and regions
News Preview
GOTHENBURG, Sweden, July 18, 2025 /PRNewswire/ -- "The positive start to 2025 continued in the second quarter, with stable organic growth in order intake and sales, and our margins strengthened despite strong headwinds from tariffs and negative currency effects," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales...
Themefolio
Profiler
Peergroup
© PR Newswire
18.07.2025
GETI B
LISTED
STO
Getinge Interim Report April-June 2025: Continuing positive trend with stable organic sales growth in all business areas and regions
News Preview
GOTHENBURG, Sweden, July 18, 2025 /PRNewswire/ -- "The positive start to 2025 continued in the second quarter, with stable organic growth in order intake and sales, and our margins strengthened despite strong headwinds from tariffs and negative currency effects," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.07.2025
ORNBV
LISTED
HEL
Orion Corporation’s financial reporting and Annual General Meeting in 2026
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 18 JULY 2025 at 9.30 EEST ...
Themefolio
Profiler
Peergroup
© BusinessWire
17.07.2025
EHAB
LISTED
NYSE
Enhabit Home Health & Hospice Announces Date of 2025 Second Quarter Earnings Call
News Preview
Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced it will report its results for the second quarter ended June 30, 2025, on Aug. 6, 2025, and host a webcast and conference call on Aug. 7, 2025. Individuals who would like to participate in the conference call webcast should join 15 minutes before the s...
Themefolio
Profiler
Peergroup
© ActuNews
17.07.2025
ALTHX
LISTED
EURONEXT
THERANEXUS : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONFIÉ À PORTZAMPARC
News Preview
Lyon, France – 17 juillet 2025, 18h00 CET – Theranexus, société biopharmaceutique innovante dans le traitement des maladies neurologiques rares, publie aujourd'hui le bilan semestriel de son contrat de liquidité confié à Portzamparc.
Au titre du contrat de liquidité confié par la soci...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
News Preview
OSE Immunotherapeutics Launches Newsletter for Individual Shareholders...
Themefolio
Profiler
Peergroup
© PR Newswire
17.07.2025
CU6
LISTED
ASX
Co-PSMA trial: Recruitment successfully completed
News Preview
SYDNEY, July 17, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT) led...
Themefolio
Profiler
Peergroup
© PR Newswire
17.07.2025
INDV
LISTED
NASDAQ
Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st
News Preview
RICHMOND, Va., July 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced that it will report second quarter 2025 financial results on Thursday, July 31, 2025 at 7:00 a.m. U.S. ET. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host...
Themefolio
Profiler
Peergroup
© ActuNews
17.07.2025
OXUR
LISTED
EURONEXT
Oxurion verzekert financiering voor de overname van Axiodis CRO en beoogt een closing op 1 augustus 2025
News Preview
Leuven, BELGIË – 17 juli 2025 – 8u30 CET – Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, kondigt aan dat het de financiering heeft verzekerd voor de overname van 72% van het kapitaal van Axiodis CRO, na een grondig due diligence-proces en de vervulling van alle opschortende voor...
Themefolio
Profiler
Peergroup
© ActuNews
17.07.2025
OXUR
LISTED
EURONEXT
Oxurion Secures Financing for the Acquisition of Axiodis CRO and Targets Closing on August 1, 2025
News Preview
Leuven, BELGIUM – July 17, 2025 at 8:30 AM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces it has secured the financing for the acquisition of 72% of the share capital of Axiodis CRO, following a rigorous due diligence process and the fulfilment of all conditions precedent. The financing has b...
Themefolio
Profiler
Peergroup
© ActuNews
17.07.2025
OXUR
LISTED
EURONEXT
Oxurion sécurise le financement de l'acquisition d'Axiodis CRO et projette un closing de l'opération au 1eraoût 2025
News Preview
Louvain, BELGIQUE – 17 juillet 2025 – 8h30, Oxurion NV (Euronext Bruxelles : OXUR), entreprise biopharmaceutique basée à Louvain, annonce la sécurisation du financement de l'acquisition de 72 % du capital d'Axiodis CRO, à l'issue d'un processus rigoureux de due diligence et après l...
Themefolio
Profiler
Peergroup
© ActuNews
17.07.2025
OXUR
LISTED
EURONEXT
Oxurion verzekert financiering voor de overname van Axiodis CRO en beoogt een closing op 1 augustus 2025
News Preview
Leuven, BELGIË – 17 juli 2025 – 8u30 CET – Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, kondigt aan dat het de financiering heeft verzekerd voor de overname van 72% van het kapitaal van Axiodis CRO, na een grondig due diligence-proces en de vervulling van alle opschortende voor...
Themefolio
Profiler
Peergroup
© ActuNews
17.07.2025
OXUR
LISTED
EURONEXT
Oxurion Secures Financing for the Acquisition of Axiodis CRO and Targets Closing on August 1, 2025
News Preview
Leuven, BELGIUM – July 17, 2025 at 8:30 AM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces it has secured the financing for the acquisition of 72% of the share capital of Axiodis CRO, following a rigorous due diligence process and the fulfilment of all conditions precedent. The financing has b...
Themefolio
Profiler
Peergroup
© ActuNews
17.07.2025
OXUR
LISTED
EURONEXT
Oxurion sécurise le financement de l'acquisition d'Axiodis CRO et projette un closing de l'opération au 1er août 2025
News Preview
Louvain, BELGIQUE – 17 juillet 2025 – 8h30, Oxurion NV (Euronext Bruxelles : OXUR), entreprise biopharmaceutique basée à Louvain, annonce la sécurisation du financement de l'acquisition de 72 % du capital d'Axiodis CRO, à l'issue d'un processus rigoureux de due diligence et après l...
Themefolio
Profiler
Peergroup
© PR Newswire
17.07.2025
VITR
LISTED
STO
Vitrolife AB: Interim report Q2, 2025: Strong performance across Consumables
News Preview
GOTHENBURG, Sweden, July 17, 2025 /PRNewswire/ --
Second quarter
Sales of SEK 871 (941) million, a flat growth in local currencies and a 7% decrease in SEK, due to a significant currency impact of -8%. Organic growth in local currencies excluding discontinued business was 3%.Sales per region, in local currencies was -3% in EMEA, +5% excluding d...
Themefolio
Profiler
Peergroup
© PR Newswire
17.07.2025
HNSA
LISTED
STO
Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results
News Preview
Hansa secures directed cash share issue of approximately 232 MSEK/US $24.3M and restructures NovaQuest debt.As compared to prior year Q2 IDEFIRIX product sales increased 76%.LUND, Sweden, July 17, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced its interim report for January-June 2025.
Renée Aguiar-Luca...
Themefolio
Profiler
Peergroup
© PR Newswire
17.07.2025
HNSA
LISTED
STO
Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results
News Preview
Hansa secures directed cash share issue of approximately 232 MSEK/US $24.3M and restructures NovaQuest debt.As compared to prior year Q2 IDEFIRIX product sales increased 76%.LUND, Sweden, July 17, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced its interim report for January-June 2025.
Renée Aguiar-Luca...
Themefolio
Profiler
Peergroup
© Newsfile
17.07.2025
COPN
LISTED
SIX
Cosmo Announces Launch of Winlevi(R) for Treatment of Acne in Singapore and Malaysia
News Preview
Dublin, Ireland--(Newsfile Corp. - July 17, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, is pleased to announce the launch of Winlevi® (clascoterone) cream 1% in Singapore and Malaysia, marking its first entry into Southeast Asia through the partnership with H...
Themefolio
Profiler
Peergroup
© PR Newswire
17.07.2025
ZLAB
LISTED
NASDAQ
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
News Preview
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing uncertainty. The situation is further complicated by renewed regulatory scrutiny of mRNA vaccines at both fe...
Themefolio
Profiler
Peergroup
© PR Newswire
17.07.2025
ZLAB
LISTED
NASDAQ
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
News Preview
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing uncertainty. The situation is further complicated by renewed regulatory scrutiny of mRNA vaccines at both fe...
Themefolio
Profiler
Peergroup
© EQS Newswire
16.07.2025
GXI
LISTED
XETR
Gerresheimer beendet Gespräche mit Private Equity Investoren über ein potenzielles Übernahmeangebot
News Preview
Gerresheimer beendet Gespräche mit Private Equity Investoren über ein potenzielles Übernahmeangebot
Fortführung der Gespräche nicht im besten Interesse des Unternehmens und seiner Stakeholder
Fokus auf Umsetzung der Wachstumsstrategie
Strategische Überprüfung Moulded Glass wird beschleunigt
Capital Market Day mit Strategie-Update im Oktober
Dü......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.07.2025
GXI
LISTED
XETR
Gerresheimer ends discussions with private equity investors about a potential takeover offer
News Preview
Gerresheimer ends discussions with private equity investors about a potential takeover offer
Continuation not in the best interest of the company and its stakeholders
Focus on implementation of growth strategy
Strategic review of Moulded Glass to be accelerated
Capital Market Day with strategy update in October
Duesseldorf, July 16, 2025. Gerre......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.07.2025
GXI
LISTED
XETR
Gespräche über ein potenzielles Übernahmeangebot beendet
News Preview
Gerresheimer AG: Gespräche über ein potenzielles Übernahmeangebot beendet
Der Vorstand der Gerresheimer AG (ISIN: DE000A0LD6E6, „Gerresheimer“) hat entschieden, die Gespräche mit Private Equity Investoren über ein potenzielles Übernahmeangebot zu beenden.
Nach eingehender Analyse des aktuellen Diskussionsstandes ist nach Einschätzung der Gesellsc......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.07.2025
GXI
LISTED
XETR
Discussions on potential takeover offer ended
News Preview
Gerresheimer AG: Discussions on potential takeover offer ended
Duesseldorf, July 16, 2025. The Management Board of Gerresheimer AG (ISIN: DE000A0LD6E6, "Gerresheimer") has decided to end discussions with private equity investors regarding a potential takeover offer.
After a thorough analysis of the current state of the discussions, the company ......
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2025
OSE
LISTED
EURONEXT
Half-Year Report on Liquidity Contract with Invest Securities
News Preview
Half-Year Report on Liquidity Contract with Invest Securities...
Themefolio
Profiler
Peergroup
© BusinessWire
16.07.2025
TEM
LISTED
NASDAQ
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-Low EF (ejection fraction) software, which uses AI to identify certain patients who may have a low left v...
Themefolio
Profiler
Peergroup
© BusinessWire
16.07.2025
ICLR
LISTED
NASDAQ
ICON’s Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical market research company Industry Standard Research (ISR). ICON outpaced the a...
Themefolio
Profiler
Peergroup
© PR Newswire
16.07.2025
BIOA B
LISTED
STO
The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
News Preview
STOCKHOLM, July 16, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's disease which was co-developed by Eisai and BioArctic, has received the 9th Bioindustry Award from the Japan Bio...
Themefolio
Profiler
Peergroup
© PR Newswire
16.07.2025
BIOA B
LISTED
STO
The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
News Preview
STOCKHOLM, July 16, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's disease which was co-developed by Eisai and BioArctic, has received the 9th Bioindustry Award from the Japan Bio...
Themefolio
Profiler
Peergroup
© PR Newswire
16.07.2025
SOBI
LISTED
STO
Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum
News Preview
STOCKHOLM, July 16, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025
Second Quarter 2025
Total revenue increased 13 per cent, 22 per cent at constant exchange rates, (CER)1, to SEK 6,175 M (5,442)Haematology revenue increased 27 per cent at CER to SEK 4,570 M (3,866), mainly d...
Themefolio
Profiler
Peergroup
© PR Newswire
16.07.2025
SOBI
LISTED
STO
Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum
News Preview
STOCKHOLM, July 16, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025
Second Quarter 2025
Total revenue increased 13 per cent, 22 per cent at constant exchange rates, (CER)1, to SEK 6,175 M (5,442)Haematology revenue increased 27 per cent at CER to SEK 4,570 M (3,866), mainly d...
Themefolio
Profiler
Peergroup
© Newsfile
16.07.2025
COPN
LISTED
SIX
Cosmo Accelerates Global ESG Leadership with Major Ratings Upgrades, UN Compact Commitment, and Climate Action Pledge
News Preview
Dublin, Ireland--(Newsfile Corp. - July 16, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced a major leap forward in its sustainability journey, underscoring its ambition to lead the next decade of healthcare innovation with purpose, transparency, and impact....
Themefolio
Profiler
Peergroup
© PR Newswire
15.07.2025
SOBI
LISTED
STO
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
News Preview
STOCKHOLM, July 15, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025, resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programmes resolved by the Annual General Meeting – on directed share issues of no more than 1,412,788 red...
Themefolio
Profiler
Peergroup
© PR Newswire
15.07.2025
SOBI
LISTED
STO
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
News Preview
STOCKHOLM, July 15, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025, resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programmes resolved by the Annual General Meeting – on directed share issues of no more than 1,412,788 red...
Themefolio
Profiler
Peergroup
© ActuNews
15.07.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 15 juli 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transparanti...
Themefolio
Profiler
Peergroup
© ActuNews
15.07.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – July 15, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on July 15, 2025, from Atlas...
Themefolio
Profiler
Peergroup
© EQS Newswire
15.07.2025
EUZ
LISTED
XETR
Outstanding Training Quality Once Again Awarded
News Preview
Berlin, July 15, 2025. Eckert & Ziegler SE (ISIN DE0005659700) has been recognized by the Berlin Chamber of Industry and Commerce (IHK) for the exceptional quality of its training program for the fourth time in a row. The Berlin-based healthcare company already held the award for “Excellent Training Quality” from 2019 to 2020, from 2021 to 2023......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.07.2025
EUZ
LISTED
XETR
Ausbildungsqualität erneut ausgezeichnet
News Preview
Berlin, 15. Juli 2025. Die Eckert & Ziegler SE (ISIN DE0005659700) wird zum vierten Mal in Folge von der Industrie- und Handelskammer (IHK) Berlin für die besondere Qualität seiner Ausbildung prämiert. Das Berliner Gesundheitsunternehmen war bereits von 2019 bis 2020, von 2021 bis 2023 und von 2023 bis 2025 Träger des Gütesiegels für "Exzellent......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.07.2025
GXI
LISTED
XETR
Gerresheimer erreicht A- im CDP-Rating
News Preview
Gerresheimer erreicht A- im CDP-Rating
„Leadership“-Status im Bereich Klima
Rating würdigt transparentes Management von CO2-Emissionen
Ambitioniertes Reduktionsziel: -50 % CO2-Emissionen bis 2030
Düsseldorf, 15. Juli 2025. Gerresheimer, innovativer System- und Lösungsanbieter und globaler Partner für die Pharma-, Biotech- und Kosmetikbranche, ha......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
